Calcitonin Gene-Related Peptide Modulates Heat Nociception in the Human Brain - An fMRI Study in Healthy Volunteers

Mohammad Sohail Asghar¹, Lino Becerra², Henrik B. W. Larsson³, David Borsook², Messoud Ashina¹*

¹ Danish Headache Center and Department of Neurology, Glostrup Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2600, Glostrup, Denmark, ² P.A.I.N. Group, Boston Children’s Hospital and Center for Pain and the Brain, Harvard Medical School, Boston, Massachusetts, 02453, United States of America, ³ Functional Imaging Unit, Department of Diagnostic, Glostrup Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2600, Glostrup, Denmark

* ashina@dadlnet.dk

Abstract

Background
Intravenous infusion of calcitonin-gene-related-peptide (CGRP) provokes headache and migraine in humans. Mechanisms underlying CGRP-induced headache are not fully clarified and it is unknown to what extent CGRP modulates nociceptive processing in the brain. To elucidate this we recorded blood-oxygenation-level-dependent (BOLD) signals in the brain by functional MRI after infusion of CGRP in a double-blind placebo-controlled cross-over study of 27 healthy volunteers. BOLD-signals were recorded in response to noxious heat stimuli in the V1-area of the trigeminal nerve. In addition, we measured BOLD-signals after injection of sumatriptan (5-HT₁B/₁D antagonist).

Results
Brain activation to noxious heat stimuli following CGRP infusion compared to baseline resulted in increased BOLD-signal in insula and brainstem, and decreased BOLD-signal in the caudate nuclei, thalamus and cingulate cortex. Sumatriptan injection reversed these changes.

Conclusion
The changes in BOLD-signals in the brain after CGRP infusion suggests that systemic CGRP modulates nociceptive transmission in the trigeminal pain pathways in response to noxious heat stimuli.

Introduction
Calcitonin-gene-related-peptide (CGRP) belongs to a family of peptides including adrenomedullin, amylin and calcitonin with diverse biological functions in the peripheral and in the
central nervous system [1, 2] Immunohistochemical studies have demonstrated that CGRP is present in the trigeminal ganglion and trigeminal nucleus caudalis [3–5]. CGRP is also released into the extracerebral circulation of humans during thermocoagulation of the trigeminal ganglion [6]. Furthermore, CGRP is a potent vasodilator of human arteries [7] and mediates relaxation of these arteries via activation of the CGRP(1)-type receptor [8]. A dense supply of CGRP-containing fibers is present around cerebral vessels and is believed to originate in the trigeminal ganglion [9]. The role of CGRP in neurovascular headache has been extensively studied in human provocation experiments [10–12]. Intravenous infusion of CGRP causes headache [10, 13] and dilatation of extracranial arteries [10] in healthy volunteers and migraine-like attacks in patients with migraine [11, 14, 15]. To what extent intravenous CGRP modulates nociceptive processing in the brain is unknown.

Blood-oxygenation-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) is widely used to hemodynamically map responses to pain in humans [16, 17]. A recent fMRI study showed that CGRP and sumatriptan did not modulate visual processing in humans and neither systemic CGRP nor sumatriptan has an effect on the BOLD-signal per se [18]. The latter is an important observation because CGRP is a strong vasodilator while sumatriptan is a strong vasoconstrictor and thereby theoretically may have an intrinsic effect the hemodynamic dependent BOLD-signal [10].

To date, no studies have investigated changes in the BOLD-signal in pain related brain-regions after CGRP infusion. In the present study, we hypothesized that intravenous infusion of CGRP would cause changes in the modulation of pain processing in the brain in response to noxious heat stimuli. In addition, we hypothesized that sumatriptan, a 5HT1B/1D antagonist, would reverse these changes. To test this we conducted a double-blind placebo-controlled randomized crossover BOLD-fMRI study in healthy volunteers. We applied noxious heat stimuli to the trigeminal area of V1 and recorded BOLD-signals in the brain before and after drug administration.

**Material and Design**

**Volunteers**

Thirty-one healthy volunteers were recruited to the study. We recruited participants via an announcement on a Danish website for recruitment of volunteers to health research (www.forsoegsperson.dk) and through a magazine for university students (MedicinerOrganisationernes Kommunikationsorgan (MOK)). Healthy volunteers between ages 18–55 years were eligible for inclusion in the study. Exclusion criteria were: history of a medical disorder; migraine or any other type of headache (except episodic tension-type headache less than once a month); daily intake of any medication except contraceptive; pregnant or nursing women, contraindications for MRI scans (e.g., metal fragments, claustrophobia), cardiovascular or cerebrovascular disease, or uncontrolled psychiatric disease or drug misuse. Heavy smokers and caffeine users were likewise not included in the study. All female participants used safe contraceptive methods. Enrolment was performed at Glostrup Hospital, Glostrup University of Copenhagen; Denmark.

The Ethical Committee of Copenhagen (H-KA-20060083) approved the study. All participants gave written consent after receiving detailed oral and written information and the study was conducted in accordance with the Helsinki II Declaration of 1964, as reversed in Edinburgh in 2000. The study was in addition registered in clinicaltrials.gov (NCT00363532).

**Pharmacological Interventions**

All participants were investigated twice and received infusion of 1.5 μg/min h-αCGRP (Calbiochem–Merck4Biosciences) at one investigation day and placebo (isotonic saline) at the other investigation day, the order being randomized. Simple randomization was applied. The
medicine (active and placebo) was delivered in sequentially numbered containers for each study day. The randomization code was kept separate and remained sealed until end of the trail. The randomization and packing was performed by the hospital pharmacy. Infusion took 20 min. Infusion of 1.5 μg/min of CGRP over 20 min reaches its maximum vascular effects after 30 to 45 min. Vascular changes can be measured already after 15 min and lasts between 90–180 min[12]. The two investigation days were separated by at least one week. On both experimental days the participants received 6 mg subcutaneous injection of sumatriptan (Imigrain® injection, Glaxo-Wellcome Operations, Bernard Castle, UK) 40 min after start of h-αCGRP or placebo infusion.

**Experimental procedures**

All participants reporting to the laboratory were headache free. Coffee, tea, cocoa or other methylxanthine-containing foods, beverages, and tobacco was not allowed for at least 12 h before start of the study. Subjects were placed in the supine position in the MRI room and a venous catheter (Venflon®) was inserted into the left antecubital vein for infusion. We collected blood samples to determine the baseline hematocrit, potassium and sodium levels. The subjects were monitored with ECG, end-tidal CO₂ (capnograph, Datex, Finland), blood oxygen saturation, blood pressure and heart rate (Veris monitor, Medrad, USA). MR imaging was performed on a 3.0 Tesla Philips Achieva Scanner (Philips Medical Systems, Best, The Netherlands) using a one-element phased-array receive head coil. We first obtained a reference anatomical whole-brain image and then repeatedly measured the BOLD-signal after noxious heat stimulation.

We defined time of drug administration as Tₙ₀. All variables were recorded at fixed time points on both study days (See Fig 1). The anatomical image was recorded at Tₐmin. BOLD-signal was recorded at baseline (Tₐ), after infusion of CGRP or Placebo (T₄₀) and 15 min after sumatriptan injection (T₆₀). Subcutaneous injection of sumatriptan has a T1/2 of 2h with a maximum serum concentration 10 min after injection and a bioavailability of 96% [19, 20].

**Headache.** Headache intensity was recorded at 0, 5, 10, 15, 25, 35, 45, 55, 65 min on a verbal rating scale (VRS) from 0 to 10 [0, no headache; 1, a very mild headache (including a feeling of pressing or throbbing); 10, worst imaginable headache] [21].

**Evoked Pain.** Noxious heat stimuli were delivered to the dominant side of the forehead (V1 branch of the trigeminal nerve) on both study days using a MRI compatible 1.6 x 1.6 cm contact Thermode (TSA-II with filter, Medoc Advanced Medical Systems, Ramat Yishai, Israel). The thermode permits a temporal and temperature controlled heat pain stimulation. The temperature applied for the pain stimulation was determined individually for each subject.

Study design

Fig 1. Study design: All variables were recorded at fixed time points throughout the study. The anatomical image was recorded at Tₐ₁₅. BOLD-fMRI scan after noxious heat stimulation with the thermode was recorded at Tₐ (baseline), at T₄₀ and T₆₀ (15 min after sumatriptan injection). Start of infusion was defined at T₀. According to the randomization code CGRP (1.5 μg/min) or placebo was infused over 20 min. Intervention with subcutaneous injection of sumatriptan was performed at T₄₅. Hemodynamic variables, adverse event and headache intensity on the verbal rating scale (VRS) was recorded at 0, 5, 10, 15, 25, 35, 45, 55 and 65 min.

doi:10.1371/journal.pone.0150334.g001
before the start of the study, as the temperature that resulted in a pain response of 5 on the Numerical Rating Scale (NRS) [0, no pain; 10, Worst imaginable pain] [22]. This pre-defined temperature was then applied throughout both study days (For study setup see Fig 2).

During functional imaging, blocks of noxious heat stimulation (pain) were delivered from baseline blocks (no pain) at 35°C (See Fig 3).

Data acquisition and Imaging protocols

Anatomical Images: Anatomical images were acquired using a T1-weighted 3D turbo field echo sequence (128 sagittal slices 1.2 mm thick; in-plane resolution 2.4 x 2 mm; repetition time 9.7 s; echo time 4.6 ms; flip angle 8, scan duration of 491 s).

BOLD-signal: BOLD functional imaging utilized a gradient echo EPI sequence (39 slices 3.0 mm thick; slice gap 0.06 mm; field of view 192 x 192 mm; in-plane acquired resolution 3 x 3 mm; repetition time 3.0 s; echo time 35 ms, flip angle 90°. 96 volumes per 4 min 48 sec scan session.

![Stimulation paradigm](https://example.com/stimulat paradigm.png)

**Fig 3. Stimulation paradigm: During functional imaging, blocks of noxious heat stimulation (pain) were delivered from baseline blocks (no pain) at 35°C.** For noxious heat we chose the pre-determined individual temperature that corresponded to 5 on the numeric rating scale (NRS). One scan session thus consisted of 6 baseline blocks (30 s/block) that was interleaved by 5 noxious heat blocks (25 s/blocks), not including the ramp periods. The rate of temperature change was 4°C/s. The ramps were modeled in defining the explanatory variables (EVs) for fMRI data analysis.

doi:10.1371/journal.pone.0150334.g003
Slices were oriented coronally, parallel to the posterior border of the medulla oblongata, covering all structures between the brain cortex and the brainstem. The brainstem was centered in the middle of the functional scans.

fMRI Analysis

Functional images were analyzed using FMRIB Software Library (FSL) (www.fmrib.ox.ac.uk/fsl). The first two volumes of each functional scan were removed to allow equilibration of image intensities. The images from subjects who had received stimulation on the left side (8 subjects) of their face were flipped along the sagittal axis (left/right) so they could be compared to those who received stimulation to the right side of their face (19 subjects). Additional pre-processing steps included, motion-correction, brain extraction, spatial smoothing (5 mm) and temporal filtering (high pass 100 s).

Whole brain analysis was performed on the data. A full quality assurance was performed prior to the statistical analysis. All scans that passed quality assurance parameters for motion correction (< 3 mm), registration to a standard space, and visual inspection of brain extraction and were included in the following statistical analysis. Statistical results were registered to a standard atlas (MNI-152 atlas). Results were visually inspected and it was individually ensured that there was a full set of scans during noxious heat stimulation (baseline, during CGRP/Placebo infusion and after sumatriptan injection).

Individual generalized linear model (GLM) results were then fed into a fixed effects analysis model using FLAME (FMRIB’s Local Analysis of Mixed Effects). The output of this was checked for outliers using regression diagnostics.

Comparisons were made between the following BOLD scans for each study day: i. T40 (during infusion) vs. T-5 (baseline); ii. T60 (after sumatriptan injection) vs T-5 (baseline), and iii. T60 (after sumatriptan injection) vs. T40 (during infusion/pre-sumatriptan). Thresholds for the comparisons were determined using a mixture modeling approach [23]. The mixture modeling approach assigns a posterior probability to each voxel according to a classification of active, de-active or null class [23]. Based on that classification, we assign a voxel as active if it has more then 50% change of belonging (posterior probability > 0.5) to the class activation. Based on the thresholding we performed an analysis of clusters of activation to determine localized activity and its extent.

Statistical Analysis

Headache- and pain scores are presented as median and range. All remaining values are presented as mean ± SD. The area under the response curve (AUC) for headache score was calculated according to the trapezium rule.

The primary endpoints were differences in BOLD-signal: i) at T40 (during infusion) compared to T-5 (baseline); ii) at T60 (after sumatriptan injection) compared to T-5 (baseline); iii) at T60 (after sumatriptan injection) compared to T40 (during infusion/pre-sumatriptan) on the CGRP day and placebo respectively; iv) BOLD-signal at baseline on the placebo day compared to baseline on the CGRP day.

It was predetermined that direct comparison between the CGRP and placebo scans would only be performed if there were either differences in baseline BOLD-signal between the two study days or differences in BOLD-signal at T-5 (baseline) and T40 on the placebo day.

In addition, we tested for difference in AUC for headache score in the period 0 to 45 min between the two experimental days. We also tested for differences in headache score after sumatriptan on both experimental days.

Differences in physiological variables were tested using two-way ANOVA. Headache- and pain scores were tested using Wilcoxon signed rank test. Regarding the remaining non-imaging
data we tested the difference between two experimental conditions using a paired, two-way Students t test.

Five percent (p < 0.05) was accepted as the level of significance. All analysis was performed using SPSS for Mac 16.0 (SPSS Inc., Chicago, IL). For imaging data group contrast statistical maps were analyzed with a modified false-discovery rate (FDR) method [23] that uses mixture model to determine the null component. FDR is a statistical method used to correct for multiple comparisons and is the method preferred when performing BOLD-fMRI analysis by FSL [23, 24]. Thresholds of activation/deactivation were then used to determine clusters of activation (peak and volume) using in-house matlab programs (Mathworks Inc Natick, MA USA).

Results

Subjects

Of the 31 participants enrolled, 27 completed the study (10 M, 17F, Ratio: 1:1.7), with a mean age of 24.7 years (range 19 to 37 years). Two participants were excluded due to claustrophobia. One participant did not report for the second study day and we lost contact. One participant did not complete the second study day due to technical problems with thermode. No functional scan was removed due to excessive movement or movement artifacts.

Physiological Measures

Baseline blood samples showed normal hematocrit, potassium- and sodium levels. Blood pressure, heart rate, oxygen saturation, end-tidal PCO2 are shown in Table 1. No statistical significant differences were recorded between time points within each study day or between study days (P > 0.05).

Psychometric Measures

Headache. 21 (~78%) out of 27 participants reported immediate headache during CGRP infusion compared to seven (~26%) participants who reported headache during placebo (P < 0.001). The AUC for headache score (0–45 min) was larger on the CGRP day (median 70.0; Range 0–155), than on the placebo day (median 25.0; Range 0–95), (P = 0.001) (Fig 4). On the CGRP day sumatriptan did not significantly reduce median headache score although a tendency was recorded (P = 0.099) (See Fig 5).

Evoked Pain: Pain scores after heat stimulus. A mean temperature of 47.2°C ± 0.56 (Range 46°C–48°C) resulted in a pain score of 5 on the NRS scale at baseline. There was no difference in baseline NRS score between the two experimental days (P = 1.0). Median pain score increased from NRS 5 (pre-treatment) to NRS 6 (post-treatment) on both study days, and there were no differences between study days (Z = -0.095, P = 0.92). Sumatriptan injection did not change the pain score on either experimental day (CGRP day; Z = -1.44 P = 0.15, Placebo day; Z = -0.062 P = 0.951) (See Fig 6).

Functional Imaging Results

Baseline. Table 2 shows the z-stats scores and coordinates for neuronal activation at baseline (before start of infusion). There was no difference in activation at baseline between the two study days.

CGRP infusion. At 40 min after of start of CGRP infusion we recorded bilateral significantly increased BOLD-signal in the brainstem and unilateral increased BOLD-signal in the insula while decreased BOLD-signal was recorded in the caudate nuclei, thalamus and cingulate cortex (see Fig 7, Table 3).
Table 1. Physiological data. Blood pressure, heart rate and End Tidal CO2 in 27 healthy volunteers. No statistical significant differences were recorded between time points within each study day or between study days (P > 0.05).

| Time  | CGRP Day | Placebo Day |
|-------|-------------------------|-------------------------|
|       | Blood Pressure          | Blood Pressure          |
|       | Systolic (±SD)          | Systolic (±SD)          |
|       | (mm Hg)                 | (mm Hg)                 |
|       | Diastolic (±SD)         | Diastolic (±SD)         |
|       | (mm Hg)                 | (mm Hg)                 |
|       | Heart rate (±SD)        | Heart rate (±SD)        |
|       | (/min)                  | (/min)                  |
|       | End Tidal CO2 (±SD)     | End Tidal CO2 (±SD)     |
|       | (mm Hg)                 | (mm Hg)                 |
| Baseline | 109.9 (±23.5)       | 116.9 (±11.4)       |
|         | 66.9 (±8.4)            | 67.3 (±8.3)            |
|         | 63.3 (±11.3)           | 64.9 (±11.8)           |
|         | 5.0 (±0.58)            | 5.1 (±0.48)            |
| T5         | 114.6 (±8.6)           | 117.0 (±11.7)         |
|         | 64.7 (±6.7)            | 66.7 (±7.9)            |
|         | 64.4 (±10.4)           | 63.6 (±11.9)           |
|         | 5.1 (±0.56)            | 5.2 (±0.50)            |
| T10        | 114.6 (±10.2)        | 117.6 (±11.3)         |
|         | 65.0 (±8.2)            | 67.7 (±8.3)            |
|         | 65.0 (±11.1)           | 65.4 (±10.9)           |
|         | 5.1 (±0.53)            | 5.2 (±0.47)            |
| T15        | 114.3 (±11.3)        | 116.9 (±11.5)         |
|         | 63.1 (±7.4)            | 67.7 (±8.2)            |
|         | 68.7 (±10.2)           | 65.5 (±10.9)           |
|         | 5.0 (±0.57)            | 5.2 (±0.50)            |
| T25        | 115.5 (±10.4)        | 116.7 (±10.3)         |
|         | 64.9 (±9.5)            | 63.2 (±8.5)            |
|         | 71.8 (±12.0)           | 66.0 (±13.5)           |
|         | 5.0 (±0.53)            | 5.0 (±0.53)            |
| T35        | 116.5 (±11.0)        | 116.7 (±10.3)         |
|         | 64.5 (±8.6)            | 63.2 (±8.5)            |
|         | 68.8 (±14.7)           | 66.0 (±13.5)           |
|         | 5.1 (±0.46)            | 5.0 (±0.49)            |
| T55        | 119.5 (±24.2)        | 117.9 (±9.6)          |
|         | 76.3 (±8.6)            | 68.1 (±6.6)            |
|         | 66.9 (±0.6)            | 67.1 (±11.8)           |
|         | 5.0 (±0.53)            | 5.1 (±0.51)            |
| T65        | 121.8 (±9.8)          | 118.4 (±9.8)          |
|         | 74.9 (±6.8)            | 69.5 (±9.5)            |
|         | 64.6 (±11.0)           | 64.2 (±10.8)           |
|         | 4.9 (±0.59)            | 5.0 (±0.52)            |

Fig 4. Headache score: Median headache score on the verbal rating scale (VRS) in 27 healthy volunteers. Black line with squares is the headache score on the CGRP day while gray line with triangles is headache score on the placebo day.
Injection of sumatriptan reversed CGRP induced changes compared to baseline (T-5). Comparison between the BOLD scan before and after sumatriptan (T40 compared to T60) revealed increased BOLD-signal in the cingulate cortex (See Fig 8, Table 4).

**Placebo infusion.** At 40 min after start of placebo infusion we recorded no statistically significant changes in BOLD-signal compared to baseline.

Injection of sumatriptan induced significantly increased BOLD-signal in the supplementary motor area and decreased BOLD-signal in the inferior frontal cortex, post-central cortex, anterior insula, thalamus and cerebellum compared to both baseline (T-5) and to the pre-sumatriptan (T40) measurements. (See Fig 9).

**Discussion**

The major findings of the present study were that intravenous infusion of CGRP modulated BOLD-signal in the brain in response to noxious heat stimuli of the trigeminal nerve without...
Table 2. Contrast analysis results for painful heat functional MRI activation at baseline (before infusion of CGRP). NOTE: Two ROIs usually active in pain (anterior cingulate cortex and anterior insula) are not identified due to the distortion of the images.

| Brain Region       | Lat. | z-stat | X (mm) | Y (mm) | Z (mm) | Vol (cm³) |
|--------------------|------|--------|--------|--------|--------|-----------|
| **Positive Activation** |      |        |        |        |        |           |
| **Cortical**       |      |        |        |        |        |           |
| Frontal            |      |        |        |        |        |           |
| Middle             | L    | 02.43  | -34    | 10     | 42     | 0.0022    |
| Supp Motor Area    | L    | 02.97  | -12    | 8      | 50     | 0.0041    |
| Supp Marginal      | R    | 02.31  | 66     | -18    | 24     | 0.0035    |
| Postcentral        | L    | 02.05  | -56    | -22    | 26     | 0.0028    |
| Supp Marginal      | R    | 02.31  | 46     | -32    | 38     | 0.0034    |
| Inferior           | R    | 03.77  | 50     | -44    | 52     | 12.03     |
| Occipital          |      |        |        |        |        |           |
| Rolandoic Operculum| L    | 02.07  | -50    | 2      | 6      | 0.0038    |
| R                  | 02.32 | 40     | -18    | 22     | 0.0029   |
| Temporal           |      |        |        |        |        |           |
| Middle             | R    | 02.18  | 60     | -30    | -4     | 0.0036    |
| Fusiform           | L    | 03.16  | -36    | -74    | -18    | 0.0728    |
| Insular            |      |        |        |        |        |           |
| Insula Posterior   | R    | 02.12  | 38     | -10    | 22     | 0.0025    |
| Insula Posterior   | L    | 02.84  | -44    | -10    | 4      | 0.0057    |
| **Brainstem / Cerebellum** |      |        |        |        |        |           |
| Pons               | R    | 02.50  | 6      | -18    | -20    | 0.0025    |
| Vermis 4 5         |      | 02.48  | -2     | -58    | -18    | 0.0058    |
| Cerebellum Crus1   | R    | 03.03  | 40     | -68    | -30    | 0.0103    |
| R                  | 02.44 | 44     | -78    | -34    | 0.1919   |
| R                  | 02.23 | 26     | -80    | -24    | 0.0031   |
| Cerebellum 6       | R    | 02.22  | 30     | -78    | -20    | 0.0025    |
| Cerebellum Crus2   | R    | 02.37  | 36     | -80    | -42    | 0.0030    |
| **Negative Activation** |      |        |        |        |        |           |
| **Cortical**       |      |        |        |        |        |           |
| Frontal            |      |        |        |        |        |           |
| Superior Orbital   | R    | 03.14  | 28     | -12    | 66     | 0.0028    |
| Precentral         | R    | 02.65  | 40     | -14    | 62     | 0.0025    |
| R                  | 03.01 | 28     | -20    | 66     | 0.0104   |
| R                  | 02.08 | 22     | -32    | 70     | 0.0052   |
| Parietal           |      |        |        |        |        |           |
| Precuneus          | L    | 05.35  | -2     | -40    | 64     | 10.53     |
| Temporal           |      |        |        |        |        |           |
| Fusiform           | L    | 03.24  | -40    | -42    | -24    | 0.0038    |
| Lingual            | L    | 03.62  | -12    | -46    | 2      | 0.0913    |
| Middle             | L    | 03.24  | -40    | -50    | 10     | 0.0034    |
| Cingulum           |      |        |        |        |        |           |
| Middle             | L    | 02.53  | -6     | -40    | 42     | 0.0029    |
| Parahippocampus    |      |        |        |        |        |           |
| Parahippocampal    | L    | 04.07  | -24    | 4      | -32    | 15.33     |
| **Sub-Cortical**   |      |        |        |        |        |           |
| Caudate            | L    | 03.05  | -10    | 20     | 4      | 0.0088    |

(Continued)
changing pain scores. Furthermore, the anti-migraine drug sumatriptan reversed these changes.

**Systemic CGRP: central or peripheral effect?**

We found that systemic administration of CGRP was associated with altered functional activation in the CNS as recorded by BOLD-fMRI. CGRP is widely distributed in the trigeminal pain pathway at the peripheral and central levels [2, 25–29]. Mechanisms responsible for CGRP induced head pain or migraine are complex and the question is whether intravenous CGRP: 1) crosses the blood brain barrier (BBB) and modulates nociception in the CNS; 2) activates and sensitizes trigeminal sensory afferents. Intravenous infusion of CGRP does not affect hemodynamics (blood pressure, heart rate, end-tidal CO2) [10, 14, 18], the cerebral blood flow (CBF) [13, 25] and visual processing [18] in man. Injection of CGRP directly into human skin or temporal muscle (i.e. in the areas of cutaneous and muscle distribution of the trigeminal afferents) did not elicit pain [30]. Furthermore, CGRP does not activate or sensitize meningeal nociceptors in rodents [31], nor does intra-thecal CGRP administration alone yield any changes [32]. In addition, CGRP reduces the discharge frequency of the wide dynamic range neurons in rats following electrical stimulation of the hind paw [33, 34], and modulates background activity and responses to brush, press and pinch to the skin of the hind paw [35, 36].

**Table 2. (Continued)**

| Brain Region | Lat. | z-stat | X (mm) | Y (mm) | Z (mm) | Vol (cm³) |
|--------------|------|--------|--------|--------|--------|-----------|
| R            | 05.03 | 10     | 18     | 0      | 00.49  |
| L            | 02.89 | -6     | 16     | 6      | 00.25  |
| R            | 05.26 | 10     | 16     | 0      | 00.06  |
| L            | 04.34 | -6     | 6      | -6     | 00.66  |
| Nac          | 04.45 | 6      | 6      | -8     | 00.85  |
| Cerebellum 4 | 03.08 | -26    | -36    | -26    | 00.27  |
| Cerebellum 8 | 03.13 | 24     | -62    | -56    | 00.51  |

**Brainstem/Cerebellum**

![Fig 7. BOLD-signal during CGRP infusion: Group BOLD-fMRI results for noxious heat simulations to the V1 area on the CGRP day; differences between neuronal activation at T40 (after CGRP infusion) and T5 (baseline). The activated regions-of-interest are shown in three projections. CGRP infusion resulted in positive activation in insula and bilateral activation in the brainstem, while negative activation was recorded in the caudate nuclei, thalamus and cingulate cortex.](doi:10.1371/journal.pone.0150334.g007)
Table 3. Contrast analysis results for painful heat functional MRI activation after CGRP infusion.

| Brain Region                  | Lat. | z-stat | X (mm) | Y (mm) | Z (mm) | Vol (cm²) |
|-------------------------------|------|--------|--------|--------|--------|-----------|
| **Positive Activation**       |      |        |        |        |        |           |
| **Cortical**                  |      |        |        |        |        |           |
| Inferior Operculum            | L    | 02.80  | -40    | 12     | 12     | 1.52      |
| Inferior Triangular           | L    | 02.45  | -30    | 32     | 4      | 0.78      |
| Inferior Orbital              | R    | 01.27  | 40     | 22     | -2     | 1.18      |
| **Insular**                   |      |        |        |        |        |           |
| InsulaAnterior                | R    | 03.19  | 32     | 22     | -2     | 0.67      |
|                               | L    | 01.90  | -32    | 0      | 16     | 0.66      |
| **Brainstem / Cerebellum**   |      |        |        |        |        |           |
| Brain Stem / Pons             | R    | 02.61  | 14     | -20    | -24    | 0.58      |
|                               | L    | 02.28  | -14    | -22    | -24    | 0.58      |
| **Negative Activation**       |      |        |        |        |        |           |
| **Cortical**                  |      |        |        |        |        |           |
| Supp Motor Area               | R    | -05.71 | 6      | 18     | 64     | 0.70      |
| Precentral Lobule             | L    | -05.05 | -8     | -38    | 62     | 0.83      |
| Precentral                    | L    | -05.24 | -30    | -8     | 62     | 0.14      |
|                               | R    | -05.24 | 32     | -32    | 54     | 0.73      |
|                               | L    | -05.68 | -52    | 0      | 46     | 0.85      |
| Middle                        | L    | -04.65 | -30    | 0      | 50     | 0.24      |
|                               | L    | -05.06 | -24    | 12     | 44     | 0.78      |
|                               | L    | -04.70 | -36    | 16     | 42     | 0.78      |
|                               | L    | -05.30 | -24    | 36     | 40     | 0.70      |
|                               | L    | -04.93 | -40    | 24     | 34     | 0.86      |
|                               | L    | -04.85 | -28    | 34     | 32     | 0.82      |
| Inferior Triangular           | L    | -05.06 | -48    | 24     | 22     | 0.78      |
|                               | L    | -04.65 | -46    | 32     | 8      | 0.16      |
| Inferior Operculum            | R    | -04.56 | 48     | 6      | 18     | 0.70      |
| Inferior Orbital              | L    | -04.84 | -36    | 24     | -16    | 0.73      |
| **Parietal**                  |      |        |        |        |        |           |
| Superior                      | R    | -05.00 | 34     | -46    | 60     | 0.86      |
| Inferior                      | R    | -04.80 | 30     | -50    | 52     | 0.10      |
|                               | L    | -05.01 | -46    | -36    | 50     | 0.11      |
|                               | L    | -04.96 | -40    | -36    | 40     | 0.23      |
| Postcentral                   | R    | -05.91 | 42     | -36    | 56     | 0.14      |
|                               | R    | -04.99 | 38     | -34    | 50     | 0.86      |
|                               | L    | -05.48 | -34    | -34    | 62     | 0.22      |
|                               | L    | -04.85 | -42    | -42    | 58     | 0.05      |
|                               | L    | -04.72 | -24    | -46    | 56     | 0.70      |
|                               | L    | -05.61 | -54    | -12    | 50     | 0.74      |
|                               | L    | -06.06 | -34    | -24    | 48     | 0.35      |
|                               | L    | -04.65 | -58    | -14    | 16     | 0.82      |
| Supramarginal                 | L    | -04.82 | -60    | -24    | 16     | 0.96      |
| Precuneus                     | L    | -04.56 | -4     | -46    | 38     | 0.15      |
|                               | L    | -05.02 | -6     | -54    | 18     | 0.06      |
| Angular                       | L    | -05.46 | -52    | -52    | 34     | 0.02      |

(Continued)
with CGRP receptor-antagonists reduce capsaisin-evoked sensitization, while post-treatment with CGRP dose-dependently restores capsaisin-evoked sensitization in rats [37]. Collectively, these data suggests that CGRP exerts its action outside of the BBB and modulates sensory processing, without direct activating or sensitizing effects.

Altered BOLD-signals in the brain after CGRP infusion

In the present study we examined BOLD-signal after noxious stimulation of ophthalmic (V1) branch of the trigeminal nerve before and after intravenous infusion of CGRP. We used noxious heat stimulation, which is a robust well-validated method that has been applied in several pain fMRI-studies [16, 38–40]. Stimulation of the ophthalmic nerve was chosen because of the trigeminal pain pathways importance in the pathophysiology of headaches.

Table 3. (Continued)

| Brain Region              | Lat. | z-stat | X (mm) | Y (mm) | Z (mm) | Vol (cm³) |
|---------------------------|------|--------|--------|--------|--------|-----------|
| Occipital                 |      |        |        |        |        |           |
| Cuneus                    | L    | -05.02 | -6     | -54    | 18     | 01.06     |
| Calcarine                 | R    | -05.06 | 10     | -70    | 18     | 00.89     |
|                           | R    | -04.54 | 10     | -60    | 18     | 02.22     |
|                           | R    | -04.75 | 12     | -66    | 10     | 00.85     |
|                           | L    | -05.19 | -12    | -62    | 14     | 03.63     |
| Cingulum                  |      |        |        |        |        |           |
| Middle                    | L    | -05.11 | 0      | -40    | 50     | 03.21     |
|                           | L    | -04.67 | -2     | -40    | 42     | 00.86     |
|                           | L    | -05.61 | 0      | -26    | 40     | 03.99     |
|                           | L    | -04.54 | 0      | 28     | 34     | 00.70     |
|                           | L    | -05.04 | 0      | -48    | 24     | 01.42     |
| Sub-Cortical              |      |        |        |        |        |           |
| Caudate                   | L    | -05.17 | -14    | 14     | 6      | 00.90     |
| Thalamus                  | L    | -04.80 | -14    | -26    | 6      | 00.90     |
| Putamen                   | L    | -04.85 | -24    | 10     | -8     | 01.09     |
| Amygdala                  | R    | -05.02 | 28     | 2      | -12    | 01.10     |
| Hippocampus               | R    | -05.14 | 32     | -6     | 20     | 01.10     |
| Brainstem/Cerebellum      |      |        |        |        |        |           |
| Cerebellum Crus 1         | R    | -04.74 | 30     | -80    | -44    | 02.95     |
| Cerebellum Crus 2         | L    | -04.64 | -14    | -82    | -24    | 01.10     |
| Cerebellum 8              | R    | -04.67 | 10     | -66    | -46    | 00.85     |

doi:10.1371/journal.pone.0150334.t003

Fig 8. BOLD-signal after sumatriptan administration: Group BOLD-fMRI results for noxious heat simulations to the V1 area on the CGRP day; differences between neuronal activation at T60 (after sumatriptan) and T40 (during CGRP infusion/before sumatriptan). The activated regions-of-interest are shown in three projections. Sumatriptan injection resulted in positive activation of the cingulate cortex.

doi:10.1371/journal.pone.0150334.g008
At baseline (before infusion), heat stimulation to the forehead resulted in significant somatotropic activation of pain-related brain centers similar to previous studies [41–44]. We observed a dropout artifact in relation to the thermode. Dropout artifacts and distortions are commonly observed when thermodes are applied to the forehead, close to the brain. To limit the effects of these distortions the slices were oriented coronally during BOLD-fMRI scans and a filter was applied to the thermode. We were not able to visualize expected anterior cingulate cortex (ACC) activation as the area was covered by the thermode (see Table 2 for z-stat scores at baseline).

Table 4. Contrast analysis results for painful heat functional MRI activation after sumatriptan administration on the CGRP day.

| Brain Region          | Lat. | z-stat | X (mm) | Y (mm) | Z (mm) | Vol (cm³) |
|-----------------------|------|--------|--------|--------|--------|-----------|
| **Positive Activation** |      |        |        |        |        |           |
| Cortical              |      |        |        |        |        |           |
| Frontal               |      |        |        |        |        |           |
| Supp Motor Area       | L    | 04.23  | -4     | 6      | 44     | 00.33     |
| **Negative Activation** |      |        |        |        |        |           |
| Cortical              |      |        |        |        |        |           |
| Frontal               |      |        |        |        |        |           |
| Middle                | L    | -2.81  | -38    | 34     | 44     | 00.27     |
| Inf. Triangular       | L    | -3.63  | -52    | 22     | 24     | 00.38     |
|                       | L    | -3.59  | -52    | 22     | 10     | 0.042     |
| Parietal              |      |        |        |        |        |           |
| Postcentral           | L    | -3.31  | -50    | -18    | 36     | 00.38     |
| Postcentral           | L    | -3.33  | -54    | -26    | 54     | 00.46     |
| Angular               | L    | -3.33  | -42    | -58    | 24     | 0.033     |
| Insular               |      |        |        |        |        |           |
| Insula Anterior       | L    | -3.35  | -38    | 18     | -6     | 0.026     |
| Sub-Cortical          |      |        |        |        |        |           |
| Thalamus              | L    | -3.11  | -6     | -14    | 14     | 0.024     |
| Brainstem/Cerebellum  |      |        |        |        |        |           |
| Cerebellum Crus 2     | R    | -3.31  | 42     | -74    | -40    | 0.043     |

doi:10.1371/journal.pone.0150334.t004

At baseline (before infusion), heat stimulation to the forehead resulted in significant somatotropic activation of pain-related brain centers similar to previous studies [41–44]. We observed a dropout artifact in relation to the thermode. Dropout artifacts and distortions are commonly observed when thermodes are applied to the forehead, close to the brain. To limit the effects of these distortions the slices were oriented coronally during BOLD-fMRI scans and a filter was applied to the thermode. We were not able to visualize expected anterior cingulate cortex (ACC) activation as the area was covered by the thermode (see Table 2 for z-stat scores at baseline).

Fig 9. BOLD-signal after sumatriptan administration: Group BOLD-fMRI results for noxious stimulation to the V1 area on the placebo day. Here differences in neuronal activation between the BOLD-fMRI scan at T₉₀ (baseline) and T₁₅₀ (after sumatriptan) is shown. Sumatriptan injection resulted in positive activation of the supplementary motor area (sup. motor area) and negative activation in the inferior frontal cortex (inf. frontal), insula and thalamus.

doi:10.1371/journal.pone.0150334.g009
After CGRP infusion we recorded changes in brain areas related to ascending pain-pathways. Specifically we recorded increased BOLD-signal in the brainstem and insula and decreased BOLD-signal in the caudate nuclei, thalamus and cingulate cortex. Brainstem activation is reported during head pain conditions such as tooth pain [44], primary headaches [45–47] and in other pain conditions such as irritable bowel syndrome [48–50], fibromyalgia [51], angina pectoris [52] and osteoarthritis [53]. The question is whether the recorded changes are due to CGRP induced headache or due to modulation of neuronal pain processing in response to noxious heat stimuli? CGRP is widely distributed in trigeminal nuclei in the brainstem [5, 54–59]. CGRP induced very mild headache (median headache score = 1.5 [which correspond to pre-pain]). Furthermore the self reported pain scores in response to noxious heat stimuli after CGRP remained unchanged. In a previous study only increased headache score after high doses of glyceryl trinitrate (GTN) was associated with changes in mechanical pain thresholds [60]. While a study of allodynia reported a low consistency between pain-thresholds in different stimulation modalities [61]. The lack of change in self-reported pain scores could therefore both be explained as a dose-response relationship due to low headache score and because of the pain stimulation modality in question.

This could suggest that the increased BOLD-signal in the brainstem is due to modulation of nociceptive input by CGRP. We recorded bilateral decreased activation in thalamus after CGRP infusion. The thalamus plays an important role in acute pain and in development of sensitivity to pain [43]. Decreased thalamic activation has been associated with modulation of pain [62] and is furthermore reported in subjects that are highly sensitive to noxious heat pain [63] or in patients with chronic neuropathic pain [62]. Our finding of decreased thalamic activation is puzzling and could indicate that CGRP may induce increased sensitivity to pain leading to reduced inhibition, increased signal transduction or reduced localization and discrimination of stimuli [64]. With the present imaging resolution we could not localize the activation to specific nuclei since it was not possible to distinguish between the respective nuclei with certainty. At baseline noxious heat stimulation resulted in bilateral insula activation. Insula activation is correlated with the intensity of pain stimulation [65, 66] resulting in bilateral insula activation after noxious heat stimulation [63, 65, 67]. Interestingly, following CGRP infusion only unilateral increased activation of insula was recorded while none of the participants reported unilateral headaches. Unilateral activation of insula has previously been recorded in pain studies of migraine attacks [45, 68]. Insula is extensively connected both to pre-frontal cortex and ACC [69]. Co-activation of insula and ACC have previously been observed [70]. However, the issue is more complex. Brain regions including the ACC and insula have multiple functions but also share some unusual anatomical features such as von Economo neurons [71]. For example the insula is involved in pain, autonomic function, interoception, salience, and awareness including detection error [72–74]. Similarly the ACC is also involved in functions that include emotion, descending analgesia, empathy, attention and salience [75, 76]. Thus, while anatomical data shows connections between the insula and numerous brain areas including anterior cingulate [77], specifically the anterior-middle region of the insula and the dorsal anterior cingulate [78], the functional relationship including co-activation [79, 80] still remains unclear [81] but clearly can be postulated that different responses (activations) may take place in these structures [78] as a result of an independent functional (e.g., the insula may be more ‘sensitive’ to salience processing) processes. The role of pharmacological agents in altering the interplay between these systems (whether peripherally or centrally acting) remains unknown.

Increased activation in caudate nuclei is associated with pain inhibition [82, 83]. Activity in the caudate nucleus during pain may also correlate to sensory activity [83]. But if this were the case a decreased activity would indicate decreased sensory integration, which should have
resulted in concomitant decreased activity in the somatosensory cortex and insula [69, 84]. Since this did not occur it is most likely that the caudate nucleus activation is instead associated with pain inhibition. There is generally consensus that the cingulate cortex plays a pivotal region for emotions and for avoidance behavior during pain [85]. The middle cingulate cortex (MCC) have motor areas that project to both the spinal cord and motor cortex and is involved in response selection [86]. Decreased activity in MCC in response to heat nociception after CGRP may reflect functionally impaired or decreased stimulus localization without altering the pain affect per se [87].

Taken together the recorded functional neuronal changes suggest nociceptive modulation from the peripheral nerve system (PNS) in response to noxious heat.

**Sumatriptan induced changes in BOLD-signal**

In the present study the sumatriptan intervention was performed to elucidate possible modulation of central pathways after CGRP infusion. We administered sumatriptan subcutaneously 45 min after intravenous administration of CGRP or placebo. BOLD-signal was then recorded 15 min after sumatriptan injection by application of pain stimulation (noxious heat) to the forehead (V1 area of the trigeminal nerve).

We found that following sumatriptan administration the subjects experienced a transient worsening of the headache. This is a well known side-effect to sumatriptan [88]. On the CGRP day sumatriptan reduced the headache with 0.5 on the VRS scale while amelioration of headache was not achieved. This is probably because the healthy subjects only experienced mild headache (VRS = 1.5) and because they were only observed for at very short time-period following sumatriptan administration (15 min). Sumatriptan also reversed the CGRP induced functional changes in response to heat noxious stimuli. Further analysis showed that compared to the CGRP-induced functional changes, sumatriptan administration resulted in additional activation of the cingulate cortex.

Even though sumatriptan is a potent vasoconstrictor, studies of healthy subjects [10, 89] and migraine patients [14, 90] have indicated that sumatriptan does not cross the blood-brain-barrier (BBB) to a large extent and that its anti-nociceptive mode-of-action is unlikely vasoconstriction. Instead it is suggested that sumatriptan inhibits neuronal transmission from first to second order neurons at the trigeminospinal level [31].

Only two previous studies have examined neuronal activation by MRI after sumatriptan administration. Krämer et al. found that after peripheral stimulation (brush), sumatriptan administration resulted in decreased activation of posterior insula while increased activation was recorded in anterior insula, orbito frontal cortex, medial thalamus and ACC [91]. A resent fMRI study in normal volunteers reported that following electrical stimulation to the leg sumatriptan administration resulted in increased activation of secondary somatosentory cortex (SII), Insula, medial thalamus and ACC [92]. Interestingly, here participants also reported increased head pain after sumatriptan. Sumatriptan is primarily used for treatment of headaches. It is therefore remarkable that none of the previous studies have examined the effects of sumatriptan on headpain (i.e. nociceptive activation of the trigeminal pain pathway and/or experimental/spontaneous headache). Therefore the previous studies only offer limited insights into interpretation of the present results.

With respect to the limitations of this study, and given that neither CGRP [10, 12, 13] nor sumatriptan [10, 89, 93] crosses the BBB or affects the BOLD-signal per se [18] our data suggest that sumatriptan reverses changes in BOLD-signals induced by CGRP by modulation of sensory afferent transmission to the CNS. This may indirectly affect the cingulate cortex, which may in turn play an important role in inhibition of head pain.
Conclusion

We found that intravenous infusion of CGRP in healthy volunteers is associated with mild headache and increased neuronal activity predominantly in the brainstem and insula; decreased neuronal activity in the caudate nuclei, thalamus and cingulate cortex. Sumatriptan reversed these changes probably by inhibiting pain transmission from the periphery to the brain without amelioration of the headache. We suggest that systemic CGRP modulates nociceptive transmission in the trigeminal pain pathways in response to heat noxious stimuli.

Author Contributions

Conceived and designed the experiments: MSA MA. Performed the experiments: MSA. Analyzed the data: MSA LB HBWL DB MA. Contributed reagents/materials/analysis tools: MSA LB HBWL MA. Wrote the paper: MSA LB HBWL DB MA.

References

1. Brain SD, Cambridge H. Calcitonin gene-related peptide: vasoactive effects and potential therapeutic role. Gen Pharmacol. 1996; 27(4):907–11. PMID: 8853291.
2. Sexton PM. Central nervous system binding sites for calcitonin and calcitonin gene-related peptide. Mol Neurobiol. 1991; 5(2–4):251–73. PMID: 1668368.
3. Chatchaisak D, Srikiatkhachorn A, Maneesri-le Grand S, Govitrarong P, Chetsawang B. The role of calcitonin gene-related peptide on the increase in transient receptor potential vanilloid-1 levels in trigeminal ganglion and trigeminal nucleus caudalis activation of rat. J Chem Neuroanat. 2013; 47:50–6. doi: 10.1016/j.jchemneu.2012.09.008 PMID: 23123284.
4. Eftekhar S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013; 14(11):1289–303. doi: 10.1016/j.jpain.2013.03.010 PMID: 23959278.
5. Kruger L, Mantyh PW, Sternini C, Brecha NC, Mantyh CR. Calcitonin gene-related peptide (CGRP) in the rat central nervous system: patterns of immunoreactivity and receptor binding sites. Brain Res. 1988; 463(2):223–44. PMID: 2848610.
6. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neuril. 1988; 23(2):193–6. doi: 10.1002/ana.410230214 PMID: 2454066.
7. Edvinsson L, Ekman R, Jansen I, Ottoosson A, Uddman R. Peptide-containing nerve fibers in human cerebral arteries: immunocytochemistry, radioimmunoassay, and in vitro pharmacology. Ann Neuril. 1987; 21(5):431–7. doi: 10.1002/ana.410210503 PMID: 2438992.
8. Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsai-cin-sensitive nerve fibres and induces vasodilation of human cerebral arteries concomitant with activation of adenyly cyclase. Cephalalgia. 1996; 16(5):310–6. PMID: 8867965.
9. McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A. 1986; 83(15):5731–5. PMID: 3488550; PubMed Central PMCID: PMC386363.
10. Asghar MS, Hansen AE, Kapijimpanga T, van der Geest RJ, Larsson HB, et al. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology. 2010; 75(17):1520–6. doi: 10.1212/WMN.0b013e31819626a PMID: 20975053.
11. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002; 22(1):54–61. PMID: 1199361.
12. Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther. 2005; 77(3):202–13. doi: 10.1016/j.cpt.2004.10.001 PMID: 15735614.
13. Petersen KA, Birk S, Lassen LH, Kruse C, Jonassen O, Lesko L, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005; 25(2):139–47. doi: 10.1111/j.1468-2982.2004.00830.x PMID: 15669861.
14. Asghar MS, Hansen AE, Amin FM, van der Geest RJ, Koning P, Larsson HB, et al. Evidence for a vascular factor in migraine. Ann Neuril. 2011; 69(4):635–45. doi: 10.1002/ana.22292 PMID: 21416486.
15. Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010; 30(10):1179–86. doi: 10.1177/0331024010368444 PMID: 20855363.

16. Brooks J, Tracey I. From nociception to pain perception: imaging the spinal and supraspinal pathways. J Anat. 2005; 207(1):19–33. doi: 10.1111/j.1469-7580.2005.00428.x PMID: 16011543; PubMed Central PMCID: PMC1571498.

17. Zambreanu L, Wise RG, Brooks JC, Iannetti GD, Tracey I. A role for the brainstem in central sensitization in humans. Evidence from functional magnetic resonance imaging. Pain. 2005; 114(3):397–407. doi: 10.1016/j.pain.2005.01.005 PMID: 15777865.

18. Asghar MS, Hansen AE, Larsson HB, Olesen J, Ashina M. Effect of CGRP and sumatriptan on the BOLD response in visual cortex. J Headache Pain. 2012; 13(2):159–66. doi: 10.1007/s10194-011-0415-4 PMID: 22246024; PubMed Central PMCID: PMC3274575.

19. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol. 1991; 31(5):291–4. PMID: 1653135.

20. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol. 1995; 47(6):543–8. PMID: 7768259.

21. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain. 1989; 38(1):17–24. PMID: 2506503.

22. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis. 1978; 37(4):378–81. PMID: 686873; PubMed Central PMCID: PMC1000250.

23. Pendse G, Borsook D, Becerra L. Enhanced false discovery rate using Gaussian mixture models for thresholding fMRI statistical maps. Neuroimage. 2009; 47(1):231–61. doi: 10.1016/j.neuroimage.2009.02.035 PMID: 19269324; PubMed Central PMCID: PMC2735129.

24. Nichols T, Hayasaka S. Controlling the familywise error rate in functional neuroimaging: a comparative review. Stat Methods Med Res. 2003; 12(5):419–46. PMID: 14599004.

25. Lassen LH, Jacobsen VB, Haderslev PA, Sperling B, Iversen HK, Olesen J, et al. Intravenous nitroglycerin as an experimental model of vascular headache. Evidence from functional magnetic resonance imaging. Pain. 2005; 114(3):397–407. doi: 10.1016/j.pain.2005.01.005 PMID: 15777865.

26. Mao J, Coghill RC, Kellstein DE, Frenk H, Mayer DJ. Calcitonin gene-related peptide enhances substance P-induced behaviors via metabolic inhibition: in vivo evidence for a new mechanism of neuromodulation. Brain Res. 1992; 574(1–2):157–63. PMID: 1379108.

27. Yu LC, Zheng EM, Lundeberg T. Calcitonin gene-related peptide 8–37 inhibits the evoked discharge frequency of wide dynamic range neurons in dorsal horn of the spinal cord in rats. Regul Pept. 1999; 83(1):21–4. PMID: 10498340.

28. Yu Y, Lundeberg T, Yu LC. Role of calcitonin gene-related peptide and its antagonist on the evoked discharge frequency of wide dynamic range neurons in the dorsal horn of the spinal cord in rats. Regul Pept. 2002; 103(1):23–7. PMID: 11738245.

29. Sun RQ, Lawand NB, Lin Q, Willis WD. Role of calcitonin gene-related peptide in the sensitization of dorsal horn neurons to mechanical stimulation after intradermal injection of capsaicin. J Neurophysiol. 2004; 92(1):320–6. doi: 10.1152/jn.00086.2004 PMID: 15212441.
36. Sun RQ, Lawand NB, Willis WD. The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin. Pain. 2003; 104(1-2):201–8. PMID: 12855330.

37. Li D, Ren Y, Xu X, Zou X, Fang L, Lin Q. Sensitization of primary afferent nociceptors induced by intradermal capsaicin involves the peripheral release of calcitonin gene-related Peptide driven by dorsal root reflexes. J Pain. 2008; 9(12):1155–68. doi: 10.1016/j.jpain.2008.06.011 PMID: 18701354; PubMed Central PMCID: PMC2642671.

38. Borsook D, Becerra L, Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov. 2006; 5(5):411–24. doi: 10.1038/nrd2027 PMID: 16604100.

39. Borsook D, Burstein R, Becerra L. Functional imaging of the human trigeminal system: opportunities for new insights into pain processing in health and disease. J Neurobiol. 2004; 61(1):107–25. doi: 10.1002/neu.20085 PMID: 15362156.

40. Upadhyay J, Knudsen J, Anderson J, Becerra L, Borsook D. Noninvasive mapping of human trigeminal brainstem pathways. Magn Reson Med. 2008; 60(5):1037–46. doi: 10.1002/mrm.21682 PMID: 18956455; PubMed Central PMCID: PMC2597480.

41. DaSilva AF, Becerra L, Makris N, Strassman AM, Gonzalez RG, Geatrakis N, et al. Somatotopic activation in the human trigeminal pain pathway. J Neurosci. 2002; 22(18):8183–92. PMID: 12223572.

42. de Leeuw R, Davis CE, Albuquerque R, Carlson CR, Andersen AH. Brain activity during stimulation of the trigeminal nerve with noxious heat. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102(6):750–7. doi: 10.1016/j.tripleo.2005.12.018 PMID: 17138177.

43. Wager TD, Atlas LY, Lindquist MA, Roy M, Woo CW, Kross E. An fMRI-based neurologic signature of physical pain. N Engl J Med. 2013; 368(15):1388–97. doi: 10.1056/NEJMoa1204471 PMID: 23574118; PubMed Central PMCID: PMC3691100.

44. Weigelt A, Terekhin P, Kempainen P, Dorfler A, Forster C. The representation of experimental tooth pain from upper and lower jaws in the human trigeminal pathway. Pain. 2010; 149(3):529–38. doi: 10.1016/pain.2010.03.027 PMID: 20382476.

45. Mayer EA, Berman S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD, et al. Differences in brain activation in patients with irritable bowel syndrome and ulcerative colitis. Pain. 2005; 115(3):398–409. doi: 10.1016/j.pain.2005.03.023 PMID: 15911167.

46. Naliboff BD, Berman S, Suyenobu B, Labus JS, Chang L, Stains J, et al. Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology. 2006; 131(2):352–65. doi: 10.1053/j.gastro.2006.05.014 PMID: 16890589.

47. Naliboff BD, Derbyshire SW, Munakata J, Berman S, Mandelkern M, Chang L, et al. Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med. 2001; 63(3):365–75. PMID: 11382264.

48. Napadow V, LaCount L, Park K, As-Sanie S, Clauw DJ, Harris RE. Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. Arthritis Rheum. 2010; 62(8):2545–55. doi: 10.1002/art.27497 PMID: 20506181; PubMed Central PMCID: PMC2921024.

49. Rosen SD, Paulus E, Frith CD, Frackowiak RS, Davies GJ, Jones T, et al. Central nervous pathways mediating angina pectoris. Lancet. 1994; 344(8916):147–50. PMID: 7912763.

50. Gwilym SE, Keltner JR, Warnaby CE, Carr AJ, Chizh B, Chessell I, et al. Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients. Arthritis Rheum. 2009; 61(9):1226–34. doi: 10.1002/art.24837 PMID: 19714588.

51. Effekhar S, Edvinsson L. Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neurosci. 2011; 12:112. doi: 10.1186/1471-2229-12-112 PMID: 22074408; PubMed Central PMCID: PMC3282678.

52. Effekhar S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010; 169(2):683–96. doi: 10.1016/j.neuroscience.2010.05.016 PMID: 20472035.

53. Inagaki S, Kito S, Kubota Y, Girgis S, Hillyard CJ, Macintyre I. Autoradiographic localization of calcitonin gene-related peptide binding sites in human and rat brains. Brain Res. 1986; 374(2):287–98. PMID: 3013366.
Yoshida A, Dostrovsky JO, Sessle BJ, Chiang CY. Trigeminal projections to the nucleus submedius of 59.

Tschopp FA, Henke H, Petermann JB, Tobler PH, Janzer R, Hokfelt T, et al. Calcitonin gene-related 58.

57.

Stover JD, Schwab CA, Matthews MA. Selective deafferentation of convergent inputs to trigeminal subnucleus caudalis: effects on calcitonin gene-related peptide distribution. Somatosens Mot Res. 1992; 9 (2):107–30. PMID: 1502661.

Tschopp FA, Henke H, Petermann JB, Tobler PH, Janzer R, Hokfelt T, et al. Calcitonin gene-related peptide and its binding sites in the human central nervous system and pituitary. Proc Natl Acad Sci U S A. 1985; 82(1):248–52. PMID: 2578663; PubMed Central PMCID: PMC397010.

59.

Yoshida A, Dostrovsky JO, Sessle BJ, Chiang CY. Trigeminal projections to the nucleus submedius of the thalamus in the rat. J Comp Neurol. 1991; 307(4):609–25. doi: 10.1002.cne.903070408 PMID: 1714465.

58.

Thomsen LL, Brennum J, Iversen HK, Olesen J. Effect of a nitric oxide donor (glyceryl trinitrate) on nociceptive thresholds in man. Cephalalgia. 1996; 16(3):169–74. PMID: 8734768.

59.

Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000; 47(5):614–24. PMID: 10805332.

60.

Iadarola MJ, Max MB, Berman KF, Byas-Smith MG, Coghill RC, Gracely RH, et al. Unilateral decrease in thalamic activity observed with positron emission tomography in patients with chronic neuropathic pain. Pain. 1995; 63(1):55–64. PMID: 8577491.

61.

Coghill RC, McHaffie JG, Yen YF. Neural correlates of interindividual differences in the subjective experience of pain. Proc Natl Acad Sci U S A. 2003; 100(14):8538–42. doi: 10.1073/pnas.1430684100 PMID: 12824463; PubMed Central PMCID: PMC1662664.

62.

Ingvar M. Pain and functional imaging. Philos Trans R Soc Lond B Biol Sci. 1999; 354(1387):1347–58. doi: 10.1098/rstb.1999.0483 PMID: 10466155; PubMed Central PMCID: PMC1692633.

63.

Coghill RC, Sang CN, Maisog JM, Iadarola MJ. Pain intensity processing within the human brain: a bilateral, distributed mechanism. J Neurophysiol. 1999; 82(4):1934–43. PMID: 10515983.

64.

Derbyshire SW, Jones AK, Gyulai F, Clark S, Townsend D, Firestone LL. Pain processing during three levels of noxious stimulation produces differential patterns of central activity. Pain. 1997; 73(3):431–45. PMID: 9469535.

65.

May A, Kaube H, Buchel C, Eichten C, Rijntjes M, Jupneter M, et al. Experimental cranial pain elicited by capsaicin: a PET study. Pain. 1998; 74(1):61–6. PMID: 9514561.

66.

Afridi SK, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RS, et al. A positron emission tomographic study in spontaneous migraine. Arch Neurol. 2005; 62(8):1270–2. doi:10.1001/archneur.62.8.1270 PMID: 16087768.

67.

Starr CJ, Sawaki L, Wittenberg GF, Burdette JH, Oshiro Y, Quevedo AS, et al. Roles of the insular cortex in the modulation of pain: insights from brain lesions. J Neurosci. 2009; 29(9):2684–94. doi: 10.1523/JNEUROSCI.5173-08.2009 PMID: 19261863; PubMed Central PMCID: PMC2748680.

68.

Peyron R, Laurent B, Garcia-Larrea L. Functional imaging of brain responses to pain. A review and meta-analysis (2000). Neurophysiol Clin. 2000; 30(5):263–88. PMID: 11126640.

69.

Allman JM, Tetreault NA, Hakeem AY, Manaye KF, Semendeferi K, Erwin JM, et al. The von Economo neurons in the frontoinsular and anterior cingulate cortex. Ann N Y Acad Sci. 2011; 1225:59–70. doi:10.1111/j.1749-6632.2011.06011.x PMID: 21534993; PubMed Central PMCID: PMC3140770.

70.

Gu X, Hof PR, Friston KJ, Fan J. Anterior insular cortex and emotional awareness. J Comp Neurol. 2010; 521(15):3371–88. doi:10.1002/cne.23368 PMID: 23749500; PubMed Central PMCID: PMC3999437.

71.

Klein TA, Ulispeger M, Danielmeier C. Error awareness and the insula: links to neurological and psychiatric diseases. Front Hum Neurosci. 2013; 7:14. doi:10.3389/fnhum.2013.00014 PMID: 23582714; PubMed Central PMCID: PMC3563042.

72.

Menon V, Uddin LQ. Saliency, switching, attention and control: a network model of insula function. Brain Struct Funct. 2010; 214(5–6):655–67. doi:10.1007/s00429-010-0262-6 PMID: 20512370; PubMed Central PMCID: PMC2898886.

73.

Devinsky O, Morrell MJ, Vogt BA. Contributions of anterior cingulate cortex to behaviour. Brain. 1995; 118 (Pt 1):279–306. PMID: 7895011.

74.

Shenhav A, Botvinick MM, Cohen JD. The expected value of control: an integrative theory of anterior cingulate cortex function. Neuron. 2013; 79(2):217–40. doi: 10.1016/j.neuron.2013.07.007 PMID: 23889936; PubMed Central PMCID: PMC3767969.

75.

Augustine JR. Circuitry and functional aspects of the insular lobe in primates including humans. Brain Res Brain Res Rev. 1996; 22(3):229–44. PMID: 8957561.

76.

Deen B, Pitskel NB, Pelphrey KA. Three systems of insular functional connectivity identified with cluster analysis. Cereb Cortex. 2011; 21(7):1498–506. doi:10.1093/cercor/bhr186 PMID: 21097516; PubMed Central PMCID: PMC3116793.
79. Fan J, Gu X, Liu X, Guise KG, Park Y, Martin L, et al. Involvement of the anterior cingulate and frontoinsular cortices in rapid processing of salient facial emotional information. Neuroimage. 2011; 54 (3):2539–46. doi: 10.1016/j.neuroimage.2010.10.007 PMID: 20937394; PubMed Central PMCID: PMC3006498.

80. Medford N, Critchley HD. Conjoint activity of anterior insular and anterior cingulate cortex: awareness and response. Brain Struct Funct. 2010; 214(5–6):535–49. doi: 10.1007/s00429-010-0265-x PMID: 20512367; PubMed Central PMCID: PMC2886906.

81. Cauda F, D'Agata F, Sacco K, Duca S, Geminiani G, Vercelli A. Functional connectivity of the insula in the resting brain. Neuroimage. 2011; 55(1):8–23. doi: 10.1016/j.neuroimage.2010.11.049 PMID: 2111053.

82. Lineberry CG, Vierck CJ. Attenuation of pain reactivity by caudate nucleus stimulation in monkeys. Brain Res. 1975; 98(1):119–34. PMID:809117.

83. Wunderlich AP, Klug R, Stubera G, Landwehrmeyer B, Weber F, Freund W. Caudate nucleus and insular activation during a pain suppression paradigm comparing thermal and electrical stimulation. Open Neuroimaj J. 2011; 5:1–8. doi:10.2174/1874440001105010001 PMID: 21643502; PubMed Central PMCID: PMC3106353.

84. Maleki N, Becerra L, Nutile L, Pendse G, Brawn J, Bigal M, et al. Migraine attacks the Basal Ganglia. Mol Pain. 2011; 7:71. doi:10.1186/1744-8069-7-71 PMID: 21936901; PubMed Central PMCID: PMC3192678.

85. MacLean P. The Triune Brain In Evolution—Role in Paleocerebral Functions. New York: First Plenum Printing; 1990.

86. Morecraft RJ, Van Hoesen GW. Cingulate input to the primary and supplementary motor cortices in the rhesus monkey: evidence for somatotopy in areas 24c and 23c. J Comp Neurol. 1992; 322(4):471–89. doi:10.1002/cne.903220403 PMID: 1383283.

87. Ploner M, Freund HJ, Schnitzler A. Pain affect without pain sensation in a patient with a postcentral lesion. Pain. 1999; 81(1–2):211–4. PMID: 10353510.

88. Visser WH, de Vriend RH, Jaspers NH, Ferrari MD. Sumatriptan-nonresponders: a survey in 366 migraine patients. Headache. 1996; 36(8):471–5. PMID: 8824001.

89. Amin FM, Asghar MS, Ravneberg JW, de Koning PJ, Larsson HB, Olesen J, et al. The effect of sumatriptan on cephalic arteries: A 3T MR-angiography study in healthy volunteers. Cephalalgia. 2013; 33(12):1009–16. doi: 10.1177/0333102413483374 PMID: 23588794.

90. Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning PJ, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol. 2013; 12(5):454–61. doi: 10.1016/S1474-4422(13)70067-X PMID: 23578775.

91. Kramer HH, Lundblad L, Birklein F, Linde M, Karlsson T, Elam M, et al. Activation of the cortical pain network by soft tactile stimulation after injection of sumatriptan. Pain. 2007; 133(1–3):72–8. doi: 10.1016/pain.2007.03.001 PMID: 17449179.

92. Yuan W, Dan L, Netra R, Shaohui M, Chenwang J, Ming Z. A pharmaco-fMRI study on pain networks induced by electrical stimulation after sumatriptan injection. Exp Brain Res. 2013; 226(1):15–24. doi: 10.1007/s00221-013-3405-8 PMID: 23329206.

93. Ashina M, Bendtsen L, Jensen R, Schiøtzer S, Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain. 2000; 86(1–2):133–8. PMID: 10779670.